Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Oculis Holding AG Warrants (OCSAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/10/2025: OCSAW (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 75.18% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/10/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.85 - 11.50 | Updated Date 02/26/2025 |
52 Weeks Range 1.85 - 11.50 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Oculis Holding AG Warrants
Company Overview
History and Background
Oculis Holding AG is a biopharmaceutical company focused on developing innovative topical ophthalmic treatments. While specific details on the founding year and early milestones of the warrants are limited, the company's evolution is tied to its drug development programs and progression through clinical trials.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and clinical trials of novel ophthalmic treatments.
- Commercialization: Involves the eventual marketing and sales of approved pharmaceutical products, contingent on successful clinical trials and regulatory approval.
- Warrants Trading: Activities related to the trading and market performance of the company's warrants (OCULW).
Leadership and Structure
Details on the leadership team and organizational structure are available on Oculis Holding AG's investor relations website. Generally, the company structure includes a board of directors, executive management, and scientific advisory board.
Top Products and Market Share
Key Offerings
- OCS-01 (Preservative-Free Topical Formulation of Dexamethasone): A potential treatment for dry eye disease (DED) and inflammation and pain following cataract surgery. Phase 3 trials are ongoing. Competitors include AbbVie (Restasis), Novartis (Xiidra), and Sun Pharma (CEQUA). Market share data is unavailable until FDA approval of OCS-01.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is characterized by increasing prevalence of eye diseases like dry eye, glaucoma, and age-related macular degeneration. The market is competitive, driven by innovation in drug delivery and therapeutic targets.
Positioning
Oculis is positioned as an emerging player with a focus on topical ophthalmic treatments. Its competitive advantage lies in its novel formulations and targeted therapies.
Total Addressable Market (TAM)
The global ophthalmic drugs market is projected to reach hundreds of billions of US dollars. Oculis's positioning relative to the TAM depends on the success of its clinical trials and eventual market penetration of approved products.
Upturn SWOT Analysis
Strengths
- Novel ophthalmic drug candidates
- Experienced management team
- Potential for significant market share if products are approved
Weaknesses
- Dependence on successful clinical trials
- Limited commercialization experience
- Relatively small size compared to major pharmaceutical companies
Opportunities
- Expanding ophthalmic market
- Potential for partnerships with larger pharmaceutical companies
- Increasing demand for topical ophthalmic treatments
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- SUN
Competitive Landscape
Oculis faces significant competition from larger, more established pharmaceutical companies. Its success depends on demonstrating the superiority of its products in clinical trials and securing regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Growth for the warrants is dependent on the growth of Oculis Holding AG and the progress of its clinical trials.
Future Projections: Future projections are speculative and depend on clinical trial outcomes and market conditions.
Recent Initiatives: Recent initiatives include advancing OCS-01 through Phase 3 trials and exploring partnerships for commercialization.
Summary
Oculis Holding AG's warrants represent a speculative investment opportunity tied to the success of the company's pipeline. The company's strengths lie in its innovative topical ophthalmic treatments and experienced management. However, it faces challenges including clinical trial risks, regulatory hurdles, and competition from larger players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Oculis Holding AG investor relations website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oculis Holding AG Warrants
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-03 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website |
Full time employees 32 | Website | ||
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.